Mesa Laboratories
Market Cap
US$957.3m
Last Updated
2019/10/23 23:41 UTC
Data Sources
Company Financials +
Executive Summary
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in Europe, Africa, Asia, South America, Australia, Canada, and Central America.
Snowflake
Fundamentals
High growth potential with excellent balance sheet.
Similar Companies
Share Price & News
How has Mesa Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.0%
MLAB
-1.6%
US Medical Equipment
0.07%
US Market
1 Year Return
20.0%
MLAB
13.8%
US Medical Equipment
8.9%
US Market
Return vs Industry: MLAB exceeded the US Medical Equipment industry which returned 13.8% over the past year.
Return vs Market: MLAB exceeded the US Market which returned 8.9% over the past year.
Shareholder returns
| MLAB | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.0% | -1.6% | 0.07% |
| 30 Day | -9.9% | -4.3% | -0.3% |
| 90 Day | -3.4% | -4.3% | -1.6% |
| 1 Year | 20.4%20.0% | 14.7%13.8% | 11.3%8.9% |
| 3 Year | 79.6%77.5% | 70.7%65.6% | 46.3%36.8% |
| 5 Year | 215.0%207.0% | 117.3%93.5% | 62.1%44.3% |
Price Volatility Vs. Market
How volatile is Mesa Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
A Close Look At Mesa Laboratories, Inc.’s (NASDAQ:MLAB) 13% ROCE4 weeks ago | Simply Wall St
Did You Miss Mesa Laboratories's (NASDAQ:MLAB) Whopping 322% Share Price Gain?1 month ago | Simply Wall St
Mesa Laboratories, Inc. (NASDAQ:MLAB) Delivered A Weaker ROE Than Its IndustryValuation
Is Mesa Laboratories undervalued compared to its fair value and its price relative to the market?
108x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MLAB ($219.65) is trading above our estimate of fair value ($183.38)
Significantly Below Fair Value: MLAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MLAB is poor value based on its PE Ratio (108x) compared to the Medical Equipment industry average (41.8x).
PE vs Market: MLAB is poor value based on its PE Ratio (108x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: MLAB is poor value based on its PEG Ratio (3.9x)
Price to Book Ratio
PB vs Industry: MLAB is overvalued based on its PB Ratio (7.2x) compared to the US Medical Equipment industry average (3.7x).
Next Steps
Future Growth
How is Mesa Laboratories forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
27.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MLAB's forecast earnings growth (27.3% per year) is above the savings rate (2.7%).
Earnings vs Market: MLAB's earnings (27.3% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MLAB's revenue (14.7% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: MLAB's revenue (14.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MLAB's Return on Equity is forecast to be high in 3 years time (22.2%)
Next Steps
Past Performance
How has Mesa Laboratories performed over the past 5 years?
-17.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: MLAB's earnings have declined by -17.9% per year over the past 5 years.
Accelerating Growth: MLAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MLAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Return on Equity
High ROE: MLAB's Return on Equity (6.6%) is considered low.
Return on Assets
ROA vs Industry: MLAB's Return on Assets is below or equal to the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: MLAB has improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is Mesa Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: MLAB's short term assets ($33.8M) exceeds its short term liabilities ($21.3M)
Long Term Liabilities: MLAB's short term assets (33.8M) exceeds its long term liabilities (19.3M)
Debt to Equity History and Analysis
Debt Level: MLAB's debt to equity ratio (16.6%) is considered satisfactory
Reducing Debt: MLAB's debt to equity ratio has reduced from 42.1% to 16.6% over the past 5 years.
Debt Coverage: MLAB's debt is well covered by operating cash flow (125.2%).
Interest Coverage: Insufficient data to determine if MLAB's interest payments on its debt are well covered by EBIT.
Balance Sheet
Inventory Level: MLAB has a low level of unsold assets or inventory.
Debt Coverage by Assets: MLAB's debt is covered by short term assets (assets are 1.7x debt).
Next Steps
Dividend
What is Mesa Laboratories's current dividend yield, its reliability and sustainability?
0.29%
Current Dividend Yield
Upcoming Dividend Payment
Purchase Mesa Laboratories before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: MLAB's dividend (0.29%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: MLAB's dividend (0.29%) is low compared to the top 25% of dividend payers in the US market (3.68%).
Stable Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MLAB is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MLAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Mesa Laboratories's salary, the management and board of directors tenure and is there insider trading?
2.9yrs
Average management tenure
CEO
Gary Owens (51yo)
2.1yrs
Tenure
US$3,270,589
Compensation
Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as ...
CEO Compensation Analysis
Compensation vs. Market: Gary has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
Management Age and Tenure
2.9yrs
Average Tenure
51yo
Average Age
Experienced Management: MLAB's management team is considered experienced (2.9 years average tenure).
Board Age and Tenure
3.3yrs
Average Tenure
56.5yo
Average Age
Experienced Board: MLAB's board of directors are considered experienced (3.3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 5,917 |
| Max Price | US$232.00 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 4,083 |
| Max Price | US$235.05 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 2,500 |
| Max Price | US$232.70 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 15,000 |
| Max Price | US$218.74 |
Ownership Breakdown
Management Team
John Sakys (50yo)
CFO, Chief Accounting Officer
- Tenure: 7yrs
- Compensation: US$1.03m
Greg DiNoia (54yo)
Senior Vice President of Commercial Operations
- Tenure: 1.9yrs
- Compensation: US$866.64k
Bryan Leo
Senior Vice President of Operations
- Tenure: 0yrs
- Compensation: US$281.45k
Garrett Krushefski
Senior Vice President of Operations
- Tenure: 0yrs
- Compensation: US$280.56k
Helene Leone
General Counsel
- Tenure: 5.8yrs
Peter Jung
VP of Corporate Development & Strategy
- Tenure: 3.7yrs
Gary Owens (51yo)
CEO, President & Director
- Tenure: 2.1yrs
- Compensation: US$3.27m
Brian Archbold
Senior Vice President of Continuous Improvement
- Tenure: 1.8yrs
Board Members
David Kelly (77yo)
Independent Director
- Tenure: 9yrs
- Compensation: US$131.33k
Evan Guillemin (53yo)
Independent Director
- Tenure: 10.7yrs
- Compensation: US$132.33k
David Perez (60yo)
Independent Director
- Tenure: 0.8yrs
- Compensation: US$69.64k
John Sullivan (66yo)
Chairman of the Board
- Tenure: 2.1yrs
- Compensation: US$146.83k
Robert Dwyer (78yo)
Independent Director
- Tenure: 13.4yrs
- Compensation: US$124.83k
John Schmieder (50yo)
Independent Director
- Tenure: 4.5yrs
- Compensation: US$124.83k
Jenny Alltoft (51yo)
Director
- Tenure: 0.6yrs
- Compensation: US$54.25k
Gary Owens (51yo)
CEO, President & Director
- Tenure: 2.1yrs
- Compensation: US$3.27m
Company Information
Mesa Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Mesa Laboratories, Inc.
- Ticker: MLAB
- Exchange: NasdaqGS
- Founded: 1982
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$957.291m
- Shares outstanding: 4.36m
- Website: https://www.mesalabs.com
Number of Employees
Location
- Mesa Laboratories, Inc.
- 12100 West Sixth Avenue
- Lakewood
- Colorado
- 80228
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MLAB | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Feb 1984 |
Biography
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in Europe, Africa, Asia, South America, Australia, Canada, and Central America. The company’s ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/23 23:41 |
| End of Day Share Price | 2019/10/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.